Boltzmann Labs

What Boltzmann Labs does

Boltzmann Labs is an AI-powered drug discovery platform company that builds a multi-agent scientific research system spanning target identification, small-molecule and biologics design, protein engineering, synthetic chemistry, and clinical research support. Founded in 2019 in Bangalore and now headquartered in Hyderabad, India, the company operates the Boltzmann AI Discovery Suite, which orchestrates domain-expert AI agents and a portfolio of proprietary models including BoltzGen for generative protein design, BiMamba RNA for linear-time RNA structure prediction, Kcatnet/KcatKm models that outperform the CatPred state-of-the-art enzyme kinetics benchmark, Boltz-DACG for intrinsically disordered protein modeling, and a QM/MM module for hybrid quantum-classical chemistry simulations. The platform is delivered through modular products (BoltChem, BoltPro, BoltBio, ReBolt, Clinbolt) covering small molecules, proteins, biologics, retrosynthesis, and clinical research, with an emerging self-driven laboratory capability announced in 2025.

The company serves pharmaceutical and biotechnology R&D teams, agrochemical and materials companies, contract research organizations, academic and translational researchers, and precision medicine programs, with named logos including GSK, L'Oreal, Morepen, RK Pharma, 4C Pharma, Aktino Pharma, Infosys Life Sciences, Johns Hopkins University, University of Maryland, and Buck Institute. Revenue derives from tiered SaaS subscriptions (Free, Starter at INR 1,800, Professional at INR 4,500, and Enterprise) on a credit-metered platform, with enterprise revenue also supported by custom AI model development, on-premise deployment, and dedicated customer management. The business is product-led growth with a freemium funnel augmented by inside-sales enterprise conversion, content marketing, an event ecosystem (BOLTZHACK, Boltz-AI-Thon, Nobel Research Sprint), and selective program memberships with Google, Microsoft, NASSCOM AI, and SINE IIT Bombay. The company has been capitalized primarily through a $100,000 pre-seed round in 2021 and an undisclosed pre-seed round from GSD Venture Studios in 2022, with headcount in the 11-50 range and operations across India, the US, UK, Germany, and France.

Name

Boltzmann Labs

Legal name

BOLTZMANN Labs Private Limited

Website

https://boltzmann.co

Company type

Private

Founded year

2019

Operating status

Operating

Headcount range

11–50 employees

Short description

Boltzmann Labs builds an AI-powered multi-agent drug discovery platform for pharma, biotech, agrochemical, materials, and academic R&D teams, offering modular tools for small molecule design, protein engineering, retrosynthesis, and clinical research via tiered SaaS subscriptions.

Ownership category

akta.pro rank

Product category

AI Drug Discovery Software

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417), Software Publishers (513210), Research and Development in the Physical, Engineering, and Life Sciences (54171)

akta.pro primary industry

AI/ML Platforms for Drug Discovery & Experiment Optimization (HLAGAJAO)

akta.pro secondary industries

AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening) (HLAAAIAE), Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization) (HLAAAIAC)

Keywords

• AI drug discovery
• Generative molecular design
• Computational retrosynthesis
• Protein engineering platform
• Multi-omics bioinformatics

Headquarters

HQ city

Hyderabad

HQ country

India

HQ region

Asia

Offices2 records

Markets served

GTM type

B2B

Offering type

Software

Cost components

Technology or R&D, Personnel, Infrastructure, Marketing or Sales, Operations

Revenue model

1. SaaS Platform Subscriptions: Tiered subscription model with four plans: Free (100 credits), Starter (₹1,800/2000 credits), Professional (₹4,500/5000 credits), and Enterprise (custom credits). Revenue derived from monthly/annual subscriptions with credit-based usage for AI model inference and molecular simulations.
2. Usage-Based Credits: Credit system where users consume computational credits for running AI models, molecular simulations, and DFT calculations. Credit packs scale with plan tier. Enterprise plans offer custom credit volumes with dedicated 24/7 hotline and a dedicated customer manager.
3. Professional Services & Custom AI Models: Enterprise plan includes custom AI model development and dedicated support, suggesting professional services or bespoke model training as a revenue component for large customers.

Pricing tiers

Go-to-market motion2 records

Distribution channels3 records

Marketing channels11 records

Core offering

Boltzmann Labs sells the Boltzmann AI Discovery Suite, an AI-powered multi-agent research platform that automates molecular design, property prediction, retrosynthesis, and lab execution for drug discovery and life sciences R&D. The suite is delivered as modular SaaS products (BoltChem, BoltPro, BoltBio, ReBolt, Clinbolt) accessible via cloud or on-premise deployment, with tiered subscription pricing and usage-based credit consumption.

Product overview

Boltzmann Labs operates as an AI-powered drug discovery platform company with a modular architecture centered on the Boltzmann AI Discovery Suite. The platform integrates multiple specialized modules including BoltChem (chemistry and small molecule design), BoltPro (protein engineering and antibody design), BoltBio (biological discovery and multi-omics analysis), ReBolt (SaaS research workflows), and Clinbolt (clinical and precision medicine). Built on multi-agent AI orchestration, the platform spans from target identification and molecular design through synthetic route planning and clinical research support. Additional specialized tools include Boltz-2 for protein complex prediction, BoltzGen and PPIFlow for generative protein design, Boltzz and MegaDock for protein engineering, Kcatnet for enzyme kinetics, Boltz-DACG for coarse-grained simulations, BiMamba RNA for structure prediction, and the QM/MM MODULE for quantum chemistry calculations. The platform is available through tiered pricing (Free, Starter at ₹1,800, Professional at ₹4,500, and Enterprise) with API access on Professional and Enterprise plans.

Differentiator

Problem solved

Functional benefit

Brands

• Boltzmann AI Discovery Suite: Comprehensive AI-powered platform for drug discovery and scientific research workflows.
• BoltChem
• BoltPro
• ReBolt
• BoltBio
• Clinbolt

Products and services

• Boltzmann AI Discovery Suite
• BoltChem
• BoltPro
• BoltBio
• ReBolt
• Clinbolt

Quantifiable outcome

• AI capable of cutting early-stage drug development costs by 50-60% compared to traditional methods
• +2 more outcomes

Named customers9 records

Segments8 records

Ideal customer profiles5 records

Technology focussed Yes

API detail

Has API

Yes

API docs

API detail

Core technology

AI maturity

App detail

AI capability17 records

Feature16 records

Partnerships

Six partnerships are on record, tiered core and minor.

• NASSCOM AIcoreStrategic or Co-development Partner · 1 January 2024Partnership with NASSCOM AI incubation program for AI innovation and startup development support, announced alongside the Boltbio alpha and Multi Agents beta launches.
• SINE (IIT Bombay)coreStrategic or Co-development Partner · 1 January 2024Incubation partnership with SINE (Society for Innovation and Entrepreneurship) at IIT Bombay, supporting deep-tech and science-based startup development. Announced alongside the Boltbio alpha and Multi Agents beta launches.
• Indian Pharmaceutical LeaderscoreStrategic or Co-development Partner · 1 January 2023Collaborations with leading Indian pharmaceutical companies established in 2023 alongside the launch of the ReBolt SaaS platform and BoltPro beta. Active in the Indian pharma ecosystem as recognized by biospectrumindia reporting.
• US Biotech Firm (unnamed)coreStrategic or Co-development Partner · 1 January 2022Key strategic partnership formed in 2022 with a US-based biotechnology firm for joint development in AI-driven drug discovery. Represents one of two key partnerships formed during the company's expansion phase.
• Top Research Lab (unnamed)coreStrategic or Co-development Partner · 1 January 2022Partnership with a top research laboratory established in 2022 as part of the company's strategic collaboration efforts. Joint development in scientific AI and research methodologies.
• Joint Venture (unnamed)minorStrategic or Co-development Partner · 1 January 2022A joint venture entity established in 2022 as part of the company's expansion and co-development strategy.

Scale indicators3 records

Recent moves7 records

Expansion highlights5 records

Direct peers

• Atomwise: AI small molecule design platform using structure-based virtual screening and generative models — directly comparable to Boltzmann's BoltChem module and protein-ligand design capabilities.
• Schrödinger: Computational chemistry and molecular simulation platform provider serving pharma and materials science — comparable to Boltzmann's BoltChem, QM/MM, and coarse-grained molecular modeling capabilities.
• Absci: AI generative biology company combining wet-lab validation with computational protein design — comparable to Boltzmann's BoltBio, BoltPro, and self-driven lab strategy for biologics discovery.
• BenevolentAI: AI drug discovery company combining knowledge graphs, target identification, and clinical development — comparable to Boltzmann's biological discovery, multi-omics integration, and clinical research modules.
• Iambic Therapeutics: AI drug discovery company built on foundation models for chemistry and protein structure prediction — closely analogous to Boltzmann's Boltz-2/BoltzGen architecture and multi-agent discovery approach.
• Exscientia: AI-driven small molecule drug discovery company with end-to-end capabilities from target to clinical — closely comparable to Boltzmann's small molecule design and property prediction modules.
• XtalPi: AI + quantum physics drug discovery platform combining molecular simulation, generative chemistry, and lab automation — a near-direct competitor across small molecule design, retrosynthesis, and autonomous experimentation.
• Insilico Medicine: AI-driven drug discovery company operating an end-to-end platform spanning target identification, generative chemistry, and clinical development — the closest analog to Boltzmann's vertically integrated AI Discovery Suite in both small molecules and biologics.
• Recursion Pharmaceuticals: AI-native drug discovery platform combining high-throughput biology, generative chemistry, and closed-loop wet-lab automation — directly comparable to Boltzmann's multi-modal discovery stack and emerging self-driven lab strategy.

Emerging players

• Cradle Bio: AI protein engineering platform focused on designing and optimizing novel proteins — directly comparable to Boltzmann's BoltPro module, BoltzGen, and PPIFlow protein design capabilities.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key highlights7 records

Customer concentration

• Xx.com/LabsBoltzmann
• LinkedInlinkedin.com/company/boltzmann-labs-pvt-ltd
• Instagraminstagram.com/boltzmannlabs1
• Facebookfacebook.com/boltzmann.labs

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds2 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Boltzmann Labs